Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients

Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients

Vemurafenib is an inhibitor of the BRAF mutation and has been approved by the Food and Drug Administration as a treatment option for patients with unresectable melanoma without brain metastasis. In the literature, vemurafenib has been reported to be also effective against brain metastasis. We encoun...

Full description

Bibliographic Details
Main Authors: Keisuke Imafuku, Koji Yoshino, Kei Yamaguchi, Satoshi Tsuboi, Kuniaki Ohara, Hiroo Hata
Format: Article
Language:English
Published: Karger Publishers 2017-04-01
Series:Case Reports in Oncology
Subjects:
Malignant melanoma
Vemurafenib
Brain metastasis
Drug resistance
BRAF mutation
Heterogeneous lesion
LDH
Online Access:http://www.karger.com/Article/FullText/461576

Internet

http://www.karger.com/Article/FullText/461576

Similar Items